Damora Therapeutics, Inc.
DMRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001800315
In the last 90 days, Damora Therapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 104 institutions reported holding it in 13F filings for Q2 2026, worth $1.67B in total; Viking Global Investors is the only superinvestor holding it.
Q4 2025 vs. Q3 2025
How the institutions holding Damora Therapeutics, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 12 | 18 | +6 |
| Shares | 170.2K | 1.11M | +937.7K (+550.9%) |
| Value | $633.3K | $65.5M | +$64.8M (+10,236.9%) |
New holders (12)
Institutions that held Damora Therapeutics, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Janus Henderson Group PLC | 1,739 | $40.0M | 0.02% |
| Ikarian Capital, LLC | 285,710 | $6.57M | 0.85% |
| FMR LLC | 238,878 | $5.50M | 0.00% |
| Jain Global LLC | 120,566 | $2.77M | 0.03% |
| Remedium Capital Partners, LLC | 120,473 | $2.77M | 1.63% |
| Point72 Asset Management, L.P. | 109,000 | $2.51M | 0.00% |
| Boothbay Fund Management, LLC | 95,798 | $2.20M | 0.06% |
| Morgan Stanley | 74,917 | $1.72M | 0.00% |
| Vanguard Group Inc | 18,247 | $419.9K | 0.00% |
| Sigma Planning Corp | 14,500 | $333.6K | 0.01% |
| Geode Capital Management, LLC | 11,573 | $266.3K | 0.00% |
| SHP Wealth Management | 25 | $575 | 0.00% |
Sold out (6)
Institutions that held Damora Therapeutics, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Novo Holdings A/S | 86,579 | $322.1K |
| Connective Capital Management, LLC | 26,956 | $100.3K |
| Two Sigma Investments, LP | 20,296 | $75.5K |
| Renaissance Technologies LLC | 15,044 | $56.0K |
| Virtu Financial LLC | 13,128 | $49.0K |
| Barclays PLC | 55 | $205 |